![](/images/graphics-bg.png)
H19-Promoter-Targeted Therapy Combined with Gemcitabine in the Treatment of Pancreatic Cancer
Joint Authors
Hochberg, Avraham
Birman, Tatiana
Hubert, Ayala
Gallula, Jennifer
Matouk, Imad
Sorin, Vladimir
Czerniak, Abraham
Ohana, Patricia
Gilon, Michal
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-06-03
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Pancreatic cancer is the eighth cancer leading cause of cancer-related death in the world and has a 5-year survival rate of 1–4% only.
Gemcitabine is a first line agent for advanced pancreatic therapy; however, its efficacy is limited by its poor intracellular metabolism and chemoresistance.
Studies have been conducted in an effort to improve gemcitabine treatment results by adding other chemotherapeutic agents, but none of them showed any significant advantage over gemcitabine monotherapy.
We found that 85% of human pancreatic tumors analyzed by in situ hybridization analyses showed moderated to strong expression of the H19 gene.
We designed a preclinical study combining gemcitabine treatment and a DNA-based therapy for pancreatic cancer using a non viral vector BC-819 (also known as DTA-H19), expressing the diphtheria toxin A chain under the control of the H19 gene regulatory sequences.
The experiments conducted either in an orthotopic and heterotopic pancreatic carcinoma animal model showed better antitumor activity following the sequential administration of the vector BC-819 and gemcitabine as compared to the effect of each of them alone.
The results presented in the current study indicate that treatment with BC-819 in combination with gemcitabine might be a viable new therapeutic option for patients with advanced pancreatic cancer.
American Psychological Association (APA)
Sorin, Vladimir& Ohana, Patricia& Gallula, Jennifer& Birman, Tatiana& Matouk, Imad& Hubert, Ayala…[et al.]. 2012. H19-Promoter-Targeted Therapy Combined with Gemcitabine in the Treatment of Pancreatic Cancer. ISRN Oncology،Vol. 2012, no. 2012, pp.1-7.
https://search.emarefa.net/detail/BIM-465051
Modern Language Association (MLA)
Sorin, Vladimir…[et al.]. H19-Promoter-Targeted Therapy Combined with Gemcitabine in the Treatment of Pancreatic Cancer. ISRN Oncology No. 2012 (2012), pp.1-7.
https://search.emarefa.net/detail/BIM-465051
American Medical Association (AMA)
Sorin, Vladimir& Ohana, Patricia& Gallula, Jennifer& Birman, Tatiana& Matouk, Imad& Hubert, Ayala…[et al.]. H19-Promoter-Targeted Therapy Combined with Gemcitabine in the Treatment of Pancreatic Cancer. ISRN Oncology. 2012. Vol. 2012, no. 2012, pp.1-7.
https://search.emarefa.net/detail/BIM-465051
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-465051